MedTrace Logo

A Study for Adult Patients With Fibromyalgia

NCT00965081 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 308

Last updated 2011-11-03

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to determine if 30 milligrams (mg) of duloxetine is effective in the treatment of fibromyalgia compared to placebo.

Conditions

  • Fibromyalgia, Primary
  • Fibromyalgia, Secondary

Interventions

DRUG

Duloxetine

30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks

DRUG

Placebo

QD po at the same time each day for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00965081 on ClinicalTrials.gov